Following successful small-animal trials that confirmed bioequivalence, BioNxt is now taking the final preclinical step to prepare its sublingual Cladribine formulation for human testing. The upcoming ...
Merck KGaA plans to phase out most animal testing in favor of new approach methodologies (NAMs) such as organs-on-a-chip and organoids over the next decade. The move aligns with a global regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results